Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant

Eric Schafer, Allen Chen, Robert J. Arceci

Research output: Contribution to journalArticlepeer-review

Abstract

Hepatosplenic T-cell lymphoma (HTCL) is a rare malignancy. Prognosis is poor with only a few case reports of long-term survivors. While HTCL universally involves the bone marrow, the condition has been most often treated with multimodal lymphoma specific chemotherapy. We report a durable, sustained first remission in an adolescent treated for HTCL who received induction therapy according to a high risk T-cell leukemia regimen, a nucleoside analog-based consolidation, and allogeneic transplantation associated with GVHD.

Original languageEnglish (US)
Pages (from-to)1127-1129
Number of pages3
JournalPediatric Blood and Cancer
Volume53
Issue number6
DOIs
StatePublished - 2009

Keywords

  • Delta gamma lymphoma
  • GVHD
  • Hepatosplenic T-cell lymphoma
  • Nucleoside analog
  • Transplant

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant'. Together they form a unique fingerprint.

Cite this